Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Glen Santangelo Barclays Bank PLC, Research Division. All right. Good morning, everybody. Why don't we get started for our first presentation? We're very excited to host Richard F ...

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead ...

Plus, the necessary guardrails around AI's role in content creation.

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for ...

Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is ...

SIPTU has said it is engaging with management at Teva Pharmaceuticals over threatened redundancies at its plant in Waterford.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Teva Pharmaceutical today and set a price target of $35.00. Schott covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, ...

There's nothing generic about this drugmaker's recent performance and continued prospects.

TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen ...

The generic drugs that Teva makes normally sell for materially less than the name-brand versions. While that leads to a steep decline in revenue for each company that originally created a now-generic ...

A $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with ...